Working… Menu
Trial record 58 of 273 for:    Betamethasone

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00670241
Recruitment Status : Completed
First Posted : May 1, 2008
Results First Posted : March 8, 2011
Last Update Posted : April 14, 2015
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
This study will compare efficacy and safety of once daily treatment of calcipotriol plus betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle alone in subjects with psoriasis vulgaris. Subjects will be treated for up to 8 weeks followed by an observation period of up to 8 weeks to investigate the occurence and the time to relapse and occurence of rebound after discontinuation of the investigational products. Only subjects with "controlled disease" will be considered for this observation phase of the study. "Controlled disease" is defined as "Clear" or "Almost Clear" severity category based on Investigator's global assessment (IGA).

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: calcipotriol and betamethasone (LEO 80185 gel) Drug: LEO 80185 vehicle Drug: Tacalcitol ointment Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 458 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Study Comparing a Gel Containing Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) With Tacalcitol Ointment (4 mcg/g) and Gel Vehicle, Used Once Daily in the Treatment of Psoriasis Vulgaris
Study Start Date : April 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : April 2009

Arm Intervention/treatment
Active Comparator: 1 Drug: calcipotriol and betamethasone (LEO 80185 gel)
Once daily application

Active Comparator: 2 Drug: Tacalcitol ointment
Once daily application

Placebo Comparator: 3 Drug: LEO 80185 vehicle
Once daily application

Primary Outcome Measures :
  1. Subjects With "Controlled Disease" ("Clear" or "Almost Clear" Disease) According to Investigator's Global Assessment of Disease Severity at Week 8 [ Time Frame: Week 8 ]

Secondary Outcome Measures :
  1. Subjects With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity at Week 4 [ Time Frame: Week 4 ]
  2. The Percentage Change in PASI From Baseline to Week 8 [ Time Frame: Baseline, Week 4 and 8 ]
    PASI is Psoriasis Area and Severity Index and is based on the investigator's assessment of extent and severity of the disease. It can range from 0 (best) to 64.8 (worst).

  3. Subjects With Relapse During the Study [ Time Frame: Week 8-16 ]
    Among subjects with controlled disease at week 8 relapse was defined as PASI exceeding the baseline PASI value minus 50% of the reduction in PASI obtained from the baseline visit to the last on-treatment visit

  4. Subjects With Rebound During the Study [ Time Frame: Week 8-16 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed and dated informed consent to be obtained prior to any trial related procedure, including wash-out
  • Clinical diagnosis of psoriasis vulgaris involving trunk and/or arms and/or legs amenable to treatment with a maximum of 100 g of LEO 80185 gel per week or 10 g per day of tacalcitol ointment
  • Disease severity graded moderate, severe or very severe according to the Investigator's global assessment (IGA) of disease severity
  • A minimum PASI score for extent of 2 in at least one body region (i.e.psoriasis affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs)
  • Subjects aged 18 years or above
  • Either sex
  • Any ethnic origin
  • Attending hospital outpatient clinic or the private practice of a dermatologist

Exclusion Criteria:

  • Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept, infliximab, adalimumab) within 3 months prior to randomisation
  • Systemic treatment with all other therapies than biologics, with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 4 weeks prior to randomisation
  • Systemic treatment with Vitamin D preparations above 500 IU per day
  • PUVA or Grenz ray therapy within 4 weeks prior to randomization
  • UVB therapy within 2 weeks prior to randomisation
  • Any topical treatment of the trunk/limbs (except for emollients) within 2 weeks prior to randomisation
  • Topical treatment for other relevant skin disorders on the face and flexures (e.g., facial and flexural psoriasis, eczema) with potent or very potent (WHO group III-IV) corticosteroids or vitamin D analogues within 2 weeks prior to randomisation
  • Topical treatment for other relevant skin disorders on the scalp (e.g. scalp psoriasis) with very potent (WHO group IV) corticosteroids or vitamin D analogues within 2 weeks prior to randomisation
  • Planned initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium) during the study
  • Current diagnosis of erythrodermic, exfoliative or pustular psoriasis
  • Subjects with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atro-phicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
  • Known or suspected disorders of calcium metabolism associated with hypercalcaemia
  • Known or suspected severe renal insufficiency or severe hepatic disorders
  • Known or suspected hypersensitivity to component(s) of the Investigational Products
  • Current participation in any other interventional clinical study
  • Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the 4-week period prior to randomisation, except for biologics (3 months)
  • Planned exposure to sun during the study that may affect psoriasis vulgaris
  • Previously randomised to this study
  • Subjects known or suspected of not being able to comply with a trial protocol (e.g. due to alcoholism, drug dependency or psychotic state)
  • Females of child-bearing potential wishing to become pregnant during the study, or are breast-feeding, or not using an adequate method of contraception during the study
  • Females of child-bearing potential with positive pregnancy test at Visit 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00670241

Layout table for location information
Canada, Nova Scotia
Eastern Canada Cutaneous Research Associates Ltd.
Halifax, Nova Scotia, Canada, B3H 1Z4
Sponsors and Collaborators
LEO Pharma
Layout table for investigator information
Principal Investigator: Richard Langley, MD Eastern Canada Cutaneous Research Associates Ltd.

Layout table for additonal information
Responsible Party: LEO Pharma Identifier: NCT00670241     History of Changes
Other Study ID Numbers: LEO 80185-G21
First Posted: May 1, 2008    Key Record Dates
Results First Posted: March 8, 2011
Last Update Posted: April 14, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone Valerate
Betamethasone benzoate
Betamethasone sodium phosphate
Skin Diseases, Papulosquamous
Skin Diseases
1 alpha,24-dihydroxyvitamin D3
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Calcium-Regulating Hormones and Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Bone Density Conservation Agents